Tag: BriaCell Therapeutics Corp.
January 22, 2020
BriaCell Invited to Present at Mount Sinai’s Frontiers in Academic Pathology Symposium at The New York Academy of Medicine
BriaCell announced that it will present at the “Frontiers in Academic Pathology” symposium, hosted by the Icahn School of Medicine... January 13, 2020
BriaCell Provides Update on Remarkable Responder
BriaCell is pleased to provide an update on the top responder in the combination study of Bria-IMT™, with Incyte’s INCMGA00012,... January 9, 2020
BriaCell Outlines New High Responding Patient Group ‘Biomarker’ Based on Cancer Grade
BriaCell is pleased to announce it has identified a new group of patients with high levels of clinical benefit in... January 7, 2020
BriaCell Ready to Seek Partners for Breast Cancer Treatment Bria-IMT
BriaCell Therapeutics Corp. (TSX:BCT,OTCQB:BCTXF) was recently featured in an article by BioTuesdays regarding the company's leading immunotherapy, Bria-IMT. January 3, 2020
BriaCell Completes Share Consolidation
BriaCell Therapeutics Corp. is pleased to announce that it has completed its previously announced consolidation of the common shares of... December 24, 2019
BriaCell Therapeutics Corp. Announces Share Consolidation
BriaCell Therapeutics Corp. announces that its Board of Directors has approved a consolidation of the Company's issued and outstanding common... December 17, 2019